Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD

from Oncology Data Advisor · host i3 Health

In this interview, Dr. Thomas Abrams of Harvard Medical School discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.

Episode metadata supplied by the publisher feed · Published Feb 8, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD

0:00 5:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Data Advisor?

This episode is 5 minutes long.

When was this Oncology Data Advisor episode published?

This episode was published on February 8, 2022.

Can I download this Oncology Data Advisor episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!